Role of lupeol and its ester on cyclophosphamide-induced hyperlipidaemic cardiomyopathy in rats

Sudharsan Periyasamy Thandavan, Y. Mythili, Sudhahar Varadarajan, P. Varalakshmi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Cyclophosphamide, an alkylating agent widely used in cancer chemotherapy, causes fatal cardiotoxicity. In this study, lupeol, a pentacyclic triterpene isolated from Crataeva nurvala stem bark, and its ester, lupeol linoleate, were investigated for their possible hypocholesterolaemic effects against cyclophosphamide-induced lipidaemic instabilities. Male albino Wistar rats were categorized into 6 groups. Group I served as control. Rats in groups II, V and Vl were injected intraperitoneally with a single dose of cyclophosphamide (200 mg kg_1) dissolved in saline. Cyclophosphamide-treated groups V and VI respectively received lupeol and lupeol linoleate (50 mg kg-1), dissolved in olive oil, for 10 days by oral gavage. Groups III and IV served as drug controls and were administered lupeol and lupeol linoleate, respectively. Cyclophosphamide administration induced abnormal changes in serum lipoproteins and lipid fractions in both serum and cardiac tissue. The activity of lipid metabolizing enzymes was distorted significantly in the cyclophosphamide-treated rats. The cyclophosphamide-treated rats also showed extensive intermuscular haemorrhage in histology. Lupeol and its ester reversed the above alterations induced by cyclophosphamide. This study encapsulates the early lipaemic abnormalities in the heart tissue of cyclophosphamide-treated rats. Treatment with lupeol linoleate was more effective than lupeol in rendering protection to the cardiac tissue challenged by cyclophosphamide.

Original languageEnglish (US)
Pages (from-to)1437-1444
Number of pages8
JournalJournal of Pharmacy and Pharmacology
Volume57
Issue number11
DOIs
StatePublished - Dec 1 2005

Fingerprint

Cardiomyopathies
Cyclophosphamide
Esters
Capparaceae
Pentacyclic Triterpenes
lupeol
Lipids
Congenital Heart Defects
Drug and Narcotic Control
Alkylating Agents
Serum
Lipoproteins
Wistar Rats
Histology
Hemorrhage
Drug Therapy
lupeol linoleate
Enzymes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Role of lupeol and its ester on cyclophosphamide-induced hyperlipidaemic cardiomyopathy in rats. / Periyasamy Thandavan, Sudharsan; Mythili, Y.; Varadarajan, Sudhahar; Varalakshmi, P.

In: Journal of Pharmacy and Pharmacology, Vol. 57, No. 11, 01.12.2005, p. 1437-1444.

Research output: Contribution to journalArticle

Periyasamy Thandavan, Sudharsan ; Mythili, Y. ; Varadarajan, Sudhahar ; Varalakshmi, P. / Role of lupeol and its ester on cyclophosphamide-induced hyperlipidaemic cardiomyopathy in rats. In: Journal of Pharmacy and Pharmacology. 2005 ; Vol. 57, No. 11. pp. 1437-1444.
@article{1b320e0f0125410c9dda7979158ff19e,
title = "Role of lupeol and its ester on cyclophosphamide-induced hyperlipidaemic cardiomyopathy in rats",
abstract = "Cyclophosphamide, an alkylating agent widely used in cancer chemotherapy, causes fatal cardiotoxicity. In this study, lupeol, a pentacyclic triterpene isolated from Crataeva nurvala stem bark, and its ester, lupeol linoleate, were investigated for their possible hypocholesterolaemic effects against cyclophosphamide-induced lipidaemic instabilities. Male albino Wistar rats were categorized into 6 groups. Group I served as control. Rats in groups II, V and Vl were injected intraperitoneally with a single dose of cyclophosphamide (200 mg kg_1) dissolved in saline. Cyclophosphamide-treated groups V and VI respectively received lupeol and lupeol linoleate (50 mg kg-1), dissolved in olive oil, for 10 days by oral gavage. Groups III and IV served as drug controls and were administered lupeol and lupeol linoleate, respectively. Cyclophosphamide administration induced abnormal changes in serum lipoproteins and lipid fractions in both serum and cardiac tissue. The activity of lipid metabolizing enzymes was distorted significantly in the cyclophosphamide-treated rats. The cyclophosphamide-treated rats also showed extensive intermuscular haemorrhage in histology. Lupeol and its ester reversed the above alterations induced by cyclophosphamide. This study encapsulates the early lipaemic abnormalities in the heart tissue of cyclophosphamide-treated rats. Treatment with lupeol linoleate was more effective than lupeol in rendering protection to the cardiac tissue challenged by cyclophosphamide.",
author = "{Periyasamy Thandavan}, Sudharsan and Y. Mythili and Sudhahar Varadarajan and P. Varalakshmi",
year = "2005",
month = "12",
day = "1",
doi = "10.1211/jpp.57.11.0009",
language = "English (US)",
volume = "57",
pages = "1437--1444",
journal = "Journal of Pharmacy and Pharmacology",
issn = "0022-3573",
publisher = "Pharmaceutical Press",
number = "11",

}

TY - JOUR

T1 - Role of lupeol and its ester on cyclophosphamide-induced hyperlipidaemic cardiomyopathy in rats

AU - Periyasamy Thandavan, Sudharsan

AU - Mythili, Y.

AU - Varadarajan, Sudhahar

AU - Varalakshmi, P.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Cyclophosphamide, an alkylating agent widely used in cancer chemotherapy, causes fatal cardiotoxicity. In this study, lupeol, a pentacyclic triterpene isolated from Crataeva nurvala stem bark, and its ester, lupeol linoleate, were investigated for their possible hypocholesterolaemic effects against cyclophosphamide-induced lipidaemic instabilities. Male albino Wistar rats were categorized into 6 groups. Group I served as control. Rats in groups II, V and Vl were injected intraperitoneally with a single dose of cyclophosphamide (200 mg kg_1) dissolved in saline. Cyclophosphamide-treated groups V and VI respectively received lupeol and lupeol linoleate (50 mg kg-1), dissolved in olive oil, for 10 days by oral gavage. Groups III and IV served as drug controls and were administered lupeol and lupeol linoleate, respectively. Cyclophosphamide administration induced abnormal changes in serum lipoproteins and lipid fractions in both serum and cardiac tissue. The activity of lipid metabolizing enzymes was distorted significantly in the cyclophosphamide-treated rats. The cyclophosphamide-treated rats also showed extensive intermuscular haemorrhage in histology. Lupeol and its ester reversed the above alterations induced by cyclophosphamide. This study encapsulates the early lipaemic abnormalities in the heart tissue of cyclophosphamide-treated rats. Treatment with lupeol linoleate was more effective than lupeol in rendering protection to the cardiac tissue challenged by cyclophosphamide.

AB - Cyclophosphamide, an alkylating agent widely used in cancer chemotherapy, causes fatal cardiotoxicity. In this study, lupeol, a pentacyclic triterpene isolated from Crataeva nurvala stem bark, and its ester, lupeol linoleate, were investigated for their possible hypocholesterolaemic effects against cyclophosphamide-induced lipidaemic instabilities. Male albino Wistar rats were categorized into 6 groups. Group I served as control. Rats in groups II, V and Vl were injected intraperitoneally with a single dose of cyclophosphamide (200 mg kg_1) dissolved in saline. Cyclophosphamide-treated groups V and VI respectively received lupeol and lupeol linoleate (50 mg kg-1), dissolved in olive oil, for 10 days by oral gavage. Groups III and IV served as drug controls and were administered lupeol and lupeol linoleate, respectively. Cyclophosphamide administration induced abnormal changes in serum lipoproteins and lipid fractions in both serum and cardiac tissue. The activity of lipid metabolizing enzymes was distorted significantly in the cyclophosphamide-treated rats. The cyclophosphamide-treated rats also showed extensive intermuscular haemorrhage in histology. Lupeol and its ester reversed the above alterations induced by cyclophosphamide. This study encapsulates the early lipaemic abnormalities in the heart tissue of cyclophosphamide-treated rats. Treatment with lupeol linoleate was more effective than lupeol in rendering protection to the cardiac tissue challenged by cyclophosphamide.

UR - http://www.scopus.com/inward/record.url?scp=34548057782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548057782&partnerID=8YFLogxK

U2 - 10.1211/jpp.57.11.0009

DO - 10.1211/jpp.57.11.0009

M3 - Article

C2 - 16259776

AN - SCOPUS:34548057782

VL - 57

SP - 1437

EP - 1444

JO - Journal of Pharmacy and Pharmacology

JF - Journal of Pharmacy and Pharmacology

SN - 0022-3573

IS - 11

ER -